More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/alpha-Galactosylceramide Analog I (water soluble) [KBC-007] [1037297-61-2]
Chemical Structure
Chemical Structure
Chemical Structure

alpha-Galactosylceramide Analog I (water soluble) [KBC-007] [1037297-61-2]

Research Use Only
AG-CR1-3608
AdipoGen Life Sciences
Estimated Purity>97% (NMR)
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Molecular Weight817.2
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    alpha-Galactosylceramide Analog I (water soluble) [KBC-007] [1037297-61-2]
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Estimated Purity
    >97% (NMR)
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C46H92N2O9
  • Molecular Weight
    817.2
  • Scientific Description
    Chemical. CAS: 1037297-61-2. Formula: C46H92N2O9. MW: 817.2. Synthetic, soluble analog of alpha-galactosylceramide (Prod. No. AG-CN2-0013). Immunostimulant. Potent stimulator of natural killer T (NKT) cells. Specific ligand of the lipid-binding MHC class I-like protein CD1d in human and mouse NKT cells. - Synthetic, soluble analog of alpha-galactosylceramide (Prod. No. AG-CN2-0013). Immunostimulant. Potent stimulator of natural killer T (NKT) cells. Specific ligand of the lipid-binding MHC class I-like protein CD1d in human and mouse NKT cells.
  • SMILES
    CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)NC(=O)CCCCCCCN(CCCCCCC)CCCCCCC
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Rational design and evaluation of a branched-chain-containing glycolipid antigen that binds to CD1d: D.J. Baek, et al.; Chem. Asian J. 5, 1560 (2010)
  • An alpha-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine: Y.S. Lee, et al.; Vaccine 29, 417 (2011)